Top PDF Acarbose for type 2 diabetes prevention.
Acarbose for type 2 diabetes prevention.
... of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, B-4000 Liège, Belgium Sir—Jean-Louis Chiasson and colleagues (June 15, p 2072) 1 report that after a mean follow-up of 3 ...
1
An integrated approach for the identification of predictive markers of type 2 diabetes
... need for more accurate assessment of the inputs and their consequences to health (Panagiotou, ...of type 2 diabetes ...compared for several parameters (clinical, biochemical parameters, ...
2
Towards a genotype-based approach for a patient-centered pharmacologic therapy of type 2 diabetes.
... variant for rs553668 is likely to cause defective insulin secretion in human pancreatic islets because of an overexpression of ADRA2A ...in type 2 diabetes ...of type 2 ...
5
Which incretin-based therapy for type 2 diabetes?
... GLP-1 RAs - exenatide LAR, dulaglutide, semaglutide, albiglutide -) with a placebo in patients with type 2 diabetes and a high cardiovascular risk profile. Although none of these trials will provide ...
7
SGLT2 versus DPP4 inhibitors for type 2 diabetes.
... Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: A 52-week randomized ...considerations for the treatment of ...
6
The endocannabinoid system: a promising target for the management of type 2 diabetes.
... with type 2 diabetes which are strongly associated with insulin resistance ...strategy for the treatment of liver fibrosis ...of type 2 diabetes ...
49
Sexually dimorphic roles for the type 2 diabetes-associated C2cd4b gene in murine glucose homeostasis.
... variant for type 2 diabetes risk at this locus [ 9 ...the diabetes risk variant rs7163757 [ 9 ] and whether it may play a role in gene expres- sion in disease-relevant tissues (notably ...
15
‘Treatment-resistant’ type 2 diabetes: Which definition for clinical practice?
... ‘Treatment-resistant’ type 2 diabetes: Which definition for clinical practice? Despite being a common feature in clinical practice and a major challenge for healthcare providers involved ...
3
Editorial. SGLT-2 receptor inhibitors: An opportunity to revise our therapeutic strategy for type 2 diabetes?
... Diabetes & Metabolism 40 (2014) S1-S3 Type 2 diabetes is among the most important and preva- lent chronic diseases, and any novel therapy that is able to address chronic hyperglycaemia is ...
3
Job strain as a risk factor for type 2 diabetes: a pooled analysis of 124,808 men and women.: Job Strain and Incident Type 2 Diabetes
... incident type 2 diabetes, with investigators masked to outcome information ...incident type 2 diabetes The outcome was the first record of type 2 diabetes, ...
27
Targeting the AMPK pathway for the treatment of Type 2 diabetes.
... Benoît Viollet, Louise Lantier, Jocelyne Devin-Leclerc, Sophie Hébrard, Chloé Amouyal, et al... Tar- geting the AMPK pathway for the treatment of Type 2 diabetes...[r] ...
3
Preventing, delaying, or masking type 2 diabetes with metformin in the diabetes prevention program?
... of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, Liège, ...the Diabetes Prevention Program (DPP) showed that withdrawal of metformin for 1-2 ...
4
Pharmacological prevention of type 2 diabetes.
... for the prevention of type 2 diabetes in high-risk individuals, especially those with IGT ...on diabetes incidence in patients with IGT or high-normal/elevated fasting glucose ...
46
Voglibose for prevention of type 2 diabetes mellitus.
... al, for the NAVIGATOR Study Group. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired ...
3
Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.
... 3.1 Effect of atorvastatin on lipid and glucose metabolism 3.1.1 Atorvastatin and lipid profile Atorvastatin is a potent synthetic HMG-CoA reductase inhibitor, which explains most of its metabolic and protective ...
15
Type 2 Diabetes Remission After Gastric Bypass: What Is the Best Prediction Tool for Clinicians?
... These models appeared to provide relatively good prediction errors between 12 and 16% [9,10], but only poorly predicted T2D remission one year after RYGB surgery in our cohort of 84 French diabetic obese subjects. This ...
22
DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.
... The safety profiles of DPP-4i [7] and SGLT2i [9] are well known. The safety profile of the DPP-4i-SGLT2i combination is comparable with that of each component prescribed separately. DPP-4i are generally well tolerated ...
37
Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.
... therapy for most individuals. [2-4] Second-line agents are diverse and increasingly ...cotransporter type 2 (SGLT2) inhibitors (gliflozins), [6] glucagon-like peptide-1 receptor agonists ...
32
Preventing and treating kidney disease in patients with type 2 diabetes
... marker, for instance reduction in albuminuria, but not clinical events of true relevance to T2DM patients, for instance need for renal replacement ...care for T2DM patients at risk of CKD [ ...
19
Skin autofluorescence predicts cancer in subjects with type 2 diabetes
... complicated type 2 ...χ 2 : p=0.001). By Cox regression analysis adjusted for age, gender, body mass index, history of smoking and renal parameters, skin autofluorescence ...
8